China NMPA Drug Inspection - Beijing Hanmi Pharmaceutical Co., Ltd. - Bacillus subtilis dual-combination live bacteria enteric-coated capsules
China NMPA drug inspection for Beijing Hanmi Pharmaceutical Co., Ltd. published June 05, 2020. Drug: Bacillus subtilis dual-combination live bacteria enteric-coated capsules. The Beijing Municipal Drug Administration released its first-quarter 2020 report (Announcement No. 18) regarding drug qu
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Beijing Hanmi Pharmaceutical Co., Ltd. published June 05, 2020. Drug: Bacillus subtilis dual-combination live bacteria enteric-coated capsules. The Beijing Municipal Drug Administration released its first-quarter 2020 report (Announcement No. 18) regarding drug qu
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox